Thousands of people in the UK and US are set to receive a bird flu vaccine as part of a government-backed trial, a proactive measure as officials prepare for the next potential global pandemic. The trial will involve 4,000 participants in both countries, supervised by the US' National Institute for Health and Care Research, to assess the effectiveness of vaccination against the H5N1 bird flu strain. This initiative comes amidst growing concerns about the virus's evolution and its potential for human-to-human transmission, which experts warn must be treated as a 'real possibility'.

Dr. Rebecca Clark, an infectious diseases expert and the trial's national co-ordinating investigator, emphasized the importance of this trial, stating that the H5N1 strain is 'evolving across animal species'. She underscored that the trial is a 'proactive attempt to shield against that possibility and any future pandemic that could emerge from it', aiming to protect people against future influenza pandemics.

The mRNA-1018 vaccine, developed by Moderna, operates by instructing the body to produce proteins related to the virus. This process trains the immune system to recognize and attack the virus upon infection, even though the antibodies do not prevent the virus from entering the body. Instead, they signal other cells to initiate the fight against the infection, thereby strengthening the immune response. This defense mechanism is anticipated to potentially lead to less severe illness in the event of an H5N1 infection.

In the UK, approximately 3,000 patients will be administered the jabs across 26 sites in England and Scotland. Participants will receive two doses of either the vaccine or a placebo control, three weeks apart. The trial is projected to run for seven months, allowing experts ample time to monitor for any unexpected effects and to assess the duration of immunity provided by the vaccine.

Experts widely agree on the urgency of such a development. Professor Paul Hunter, a leading infectious disease expert, highlighted the consistent concern that avian influenza could trigger a pandemic. He noted that current vaccines against the virus are generally less effective than those for other influenza types, making a new vaccine crucial for reducing pandemic risk. Professor Hunter also pointed out that poultry workers, who are at a greater risk of infection, would particularly benefit from an improved vaccine.

The H5N1 strain has caused widespread devastation since 2020, leading to the deaths of millions of farmed and wild birds globally. Its spread has not been limited to birds, infecting various mammals including lions, seals, foxes, cats, dogs, and most recently, dairy cattle in the US and Europe. The UK has experienced unprecedented bird flu outbreaks on poultry farms, resulting in over five million birds culled in Britain alone over the last four years.

Human infections with H5N1 have been recorded since the 1990s, with almost half of the at least 1,000 infected individuals having died. Since 2024, there have been 116 confirmed human cases worldwide, predominantly linked to close contact with infected animals. Officials are closely monitoring the situation, as experts caution that the virus could indeed trigger a human epidemic.

Dr. Richard Pebody, director of epidemic and emerging infections at the UK Health Security Agency (UKHSA), emphasized the inevitability of a future pandemic, with a flu pandemic being the most likely scenario. He stated that this trial for a new mRNA pandemic influenza vaccine is a significant step towards bolstering global capabilities to protect populations against future influenza outbreaks.

Early trials of the new jab have been encouraging, showing it to be generally well-tolerated with most side-effects being mild to moderate. Dr. Hiwot Hiruy, senior director of clinical development at Moderna, reported no safety concerns from initial trials, with an immune response detectable as early as seven days after the first injection.

External experts have also welcomed the early findings. Professor Ed Hutchinson, an expert in molecular and cellular virology, acknowledged the current low immediate risk of H5N1 to humans but stressed the virus's constant mutation. He highlighted the critical role mRNA vaccines could play in a pandemic response due to their strong protective responses, rapid 'fine-tuning' capabilities to match specific strains, and scalable manufacturing potential.

Professor John Tregoning, a vaccine expert, echoed the call for preparedness, likening vaccines for pandemic viruses to seatbelts – essential for emergencies, even if one hopes never to use them. He underscored a key lesson from the COVID-19 pandemic: the critical importance of speed in response for saving lives. Conducting a large-scale human vaccine trial for H5N1 now will enable a more rapid scale-up of response should the virus spread in the future. He commended the trial's methodology, calling it good quality research with a sufficient sample size to detect an immune response.